Syntara Limited (UUDA) AI Stock Analysis

Syntara Limited

(Frankfurt:UUDA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low LeverageThe absence of debt and sizeable equity base reduce solvency and refinancing pressure compared with earlier periods of higher leverage. This gives Syntara greater balance-sheet flexibility to support clinical development and absorb operating volatility over the next several quarters.

Negative Factors

No Recent RevenueThe absence of reported revenue means Syntara currently lacks an established commercial earnings stream to fund operations or validate market adoption. This leaves future financial performance dependent on successful development and eventual commercialisation rather than recurring business activity.

Syntara Limited (UUDA) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 36.34M
Dividend Yield: ―
Average Volume (3M): 10.50K
Price to Earnings (P/E): -3.4
Beta (1Y): -0.16
Revenue Growth: ―
EPS Growth: -3.33%
Country: Germany
Employees: 85
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Syntara Limited Business Overview & Revenue Model

Company Description

Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the compa...

Syntara Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:UUDA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:CAN	53Neutral	AUD 8.30M	0.30	64.70%	―	-24.22%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:VIT	44Neutral	AUD 13.25M	-2.98	-9.80%	―	5.74%	-222.22%
AU:EXL	43Neutral	AUD 2.72M	-0.59	-50.35%	―	-4.87%	-9.78%
AU:LGP	41Neutral	AUD 49.68M	-13.04	-1.67%	―	15.21%	-141.82%
AU:PKP	39Underperform	AUD 21.43M	-5.07	4388.00%	―	-19.73%	50.34%

* Healthcare Sector Average

Performance Comparison

DE:UUDA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:UUDA	Syntara Limited	0.01	-0.00	-8.33%
AU:EXL	Elixinol Wellness Ltd	0.01	0.00	25.00%
AU:CAN	Cann Group Ltd.	0.01	-0.00	-9.09%
AU:LGP	Little Green Pharma Ltd.	0.06	-0.07	-53.85%
AU:PKP	Althea Group Holdings Ltd.	0.02	-0.00	-15.79%
AU:VIT	Cronos Australia Ltd.	0.02	-0.04	-68.25%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Syntara Limited AI Stock Analysis